Bryan Johnson· Author
HBOT reduced my blood pTau217 by 28% (from 0.14 to 0.10 pg/mL).
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
HBOT reduced my blood pTau217 by 28% (from 0.14 to 0.10 pg/mL).
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
So, this is a specific marker for Alzheimer disease, and that declined by 28.6%.
The PAL comment, this is PAL 217. This was recently approved by the FDA as the first marker for Alzheimer's and HBO lowered that marker in me by 28%.
With that as my baseline, I started a therapy called hyperaric oxygen therapy and it lowered my levels by 28%.